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Introduction: Sunitinib is an oral multi-targeted tyrosine kinase inhibitor approved for first line treatment for
metastatic renal cell carcinoma and imatinib-resistant metastatic gastrointestinal stromal tumors. Sunitinib
administration can cause myelosuppression resulting in neutropenia and thrombocytopenia. Here we present the
case of a patient with metastatic renal cell carcinoma who developed sunitinib-induced immune-mediated
thrombocytopenia and who was treated with withdrawal of sunitinib and administration of intravenous
immunoglobulin and steroids.
Case presentation: This case report describes a 70-year-old Aboriginal Australian with a diagnosis of metastatic
renal cell carcinoma. Three weeks after the initiation of sunitinib he developed epistaxis and was admitted with
thrombocytopenia (platelets 7 × 109/L) which was found to be refractory to platelet transfusion. Sunitinib was
stopped and he was treated with intravenous immunoglobulin and steroids. His platelet count rapidly improved
and returned to baseline in three weeks. Only two cases of sunitinib-induced immune-mediated thrombocytopenia
have been described in the literature.
Conclusion: Clinicians should have a high index of suspicion for the potential of immune-mediated
thrombocytopenia after the initiation of multi-targeted tyrosine kinase inhibitors such as sunitinib. This is a
diagnosis of exclusion and can be safely treated by drug withdrawal.
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Sunitinib (SutentW) is an oral multi-targeted tyrosine
kinase inhibitor. Sunitinib inhibits members of the split-
kinase domain family of receptor tyrosine kinases (RTKs)
including the vascular endothelial growth factor recep-
tors (VEGFRs) types 1 and 2 (FLT1 and FLK1 or KDR);
platelet-derived growth factor receptors alpha and beta
(PDGFR-alpha and PDGFR-beta); the stem cell factor
receptor c-KIT; and the FLT3 and RET kinases. Inhibition
of these RTKs results in a reduction in tumor growth, pro-
gression, metastases and angiogenesis [1]. Clinically suni-
tinib is approved for the first line treatment of metastatic
renal cell carcinoma (mRCC) and imatinib-resistant meta-
static gastrointestinal stromal tumors. Reported toxicities* Correspondence: Zia.Ansari@calvarymater.org.au
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distribution, and reproduction in any mediumof sunitinib include fatigue, hypertension, diarrhea, vomi-
ting, skin toxicity (hand and foot syndrome), neutropenia
and thrombocytopenia [2]. Here we present the case
report of a patient with mRCC who developed sunitinib-
induced immune-mediated thrombocytopenia and recove-
red after the withdrawal of sunitinib and immunoglobulin
and steroid support.
Case presentation
The patient is a 70-year-old Aboriginal Australian with a
history of a left nephrectomy in 2005 for clear cell renal
cell carcinoma as well as multiple co-morbidities inclu-
ding chronic obstructive airway disease, ischemic heart
disease with coronary artery bypass graft, aortic valve
replacement on warfarin and gastroesophageal reflux
disease. His medications included fluticasone and salmete-
rol inhaler (250 and 50mcg respectively) two puffs twice a
day, furosemide 20mg in the morning, atorvastatin 40mgentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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mol 1g daily. Investigation for shortness of breath revealed
multiple metastases in both lungs, the biopsy of which
confirmed mRCC. There was no previous history of auto-
immune disease, hematological disorder, liver disease, hu-
man immunodeficiency virus, or hepatitis B or hepatitis C
infection. His baseline full blood count revealed: he-
moglobin 131g/L, white blood cell count 6.4 × 109/L
and platelets 294 × 109/L. He was commenced on
sunitinib 50mg/day. The patient did not take any new
medications, herbal or over the counter drugs since
his commencement of sunitinib. There was no evidence
of liver metastases.
A routine full blood count two weeks post-treatment
showed a decline in his platelets to 129 × 109/L, how-
ever, his hemoglobin was 161g/L and white blood cell
count was 4.9 × 109/L. In the third week he developed
epistaxis and was admitted to hospital. His platelets
dropped to 7 × 109/L and his international normalized
ratio (INR) was 2.4. This was reversed with an intraven-
ous vitamin K injection. His sunitinib and warfarin were
stopped. The epistaxis stabilized with nasal packing and
he received a platelet transfusion. His thrombocytopenia
did not respond and his platelet count dropped further
to 1 × 109/L.
On clinical examination there was evidence of oropha-
ryngeal petechiae, epistaxis and peripheral ecchymoses.
There was no fever, lymphadenopathy, hepatosplenom-
egaly or neurological signs. Laboratory investigations
included normal renal function tests, electrolytes and
stable liver function tests. Coagulation screening showed
his INR had reversed to 1.1 after intravenous vitamin K,
prothrombin time 12 seconds (11 to 15), activated par-
tial thromboplastin time 24 seconds (23 to 38) and fi-
brinogen 3.7g/L (2.0 to 4.0). Peripheral blood film
showed thrombocytopenia and no evidence of schisto-
cytosis, spherocytosis or dysplasia. There was no evi-
dence of hemolysis.
Disseminated intravascular coagulation and throm-
botic microangiopathy were ruled out as possible causes
of sunitinib-mediated thrombocytopenia by the results
of the above investigations. Platelet-bound immunoglo-
bulin and a bone marrow aspirate were not performed
when discussed with a hematologist, and the diagnosis
of exclusion, sunitinib-induced immune-mediated throm-
bocytopenia, was made. The patient was treated with in-
travenous immunoglobulin 27.5g (0.4g/kg) once daily for
five days with prednisolone 50mg once a day. His platelet
count rapidly improved to 103 × 109/L and returned to a
baseline of 259 × 109/L after three weeks.
Normalization of this patient’s platelet count following
withholding of sunitinib is consistent with the diagno-
sis of immune-mediated thrombocytopenia secondary
to sunitinib.Discussion
Drug-induced immune-mediated thrombocytopenia is
thought to be a result of antibody production in the
presence of a sensitizing medication, with the antibodies
targeting epitopes on the platelet surface, subsequently
leading to the clearance of the antibody-coated platelets
by the mononuclear phagocytic system. It takes five to
seven days of exposure to produce sensitization in a pa-
tient given the drug for the first time. Although drug-
induced thrombocytopenia is uncommon, it can have
devastating, and even fatal, consequences that can usu-
ally be prevented simply by discontinuing the causative
drug. It is therefore important that clinicians have a gen-
eral understanding of this condition and the drugs that
can cause it. Chemotherapeutic and immunosuppressive
agents typically cause thrombocytopenia by suppressing
hematopoiesis; they can also cause immune-mediated
thrombocytopenia [3]. Drug-induced thrombocytopenia
should be suspected, therefore, in patients treated with
such drugs if there is an acute drop in the platelet level
after exposure.
Thrombotic microangiopathy is another cause of suni-
tinib-mediated thrombocytopenia, reported by Kapiteijn
et al. [4]. Sunitinib is a tyrosine kinase inhibitor that
targets VEGFR-2 and PDGFR-beta, which are both the
major expression subtypes of VEGFR and PDGFR in ca-
pillary vasculature. It is hypothesized that sunitinib acts
via direct anti-VEGFR and anti-PDGFR effects that re-
sult in damage of the capillary endothelium [4].
Sunitinib has been associated with other autoimmune
disorders such as hypothyroidism; therefore, the possi-
bility of an immunologic phenomenon to account for
sunitinib-induced immune-mediated thrombocytopenia
is reasonable [5,6]. However, the exact mechanism by
which sunitinib induces an immune-mediated thrombo-
cytopenia is unknown. In a phase III trial of metastatic
renal cell cancer patients, Motzer et al. reported some
grade of thrombocytopenia in 65 of 375 patients ran-
domized to sunitinib treatment, with eight of the 65
(12%) having grade 3 thrombocytopenia [7].
Renal cell carcinoma is also associated with immune-
mediated thrombocytopenia [8,9]. Therefore, we can-
not rule out the possibility that the immune-mediated
thrombocytopenia was related to renal cell carcinoma.
However, in our case, sunitinib administration after
the diagnosis of renal cell carcinoma resulting in throm-
bocytopenia resolving completely upon drug withdrawal
is consistent with sunitinib-induced immune-mediated
thrombocytopenia.
There have been two cases of sunitinib-induced im-
mune-mediated thrombocytopenia reported to date. In
both cases patients were treated with intravenous im-
munoglobulin 1g/kg over two days and intravenous tran-
examic acid [10,11].
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In this case thrombocytopenia following the initiation of
the multi-targeted tyrosine kinase inhibitors, sunitinib,
was safely treated by drug withdrawal. When treating
patients with these agents clinicians should have a high
index of suspicion for the potential of immune-mediated
thrombocytopenia which is a diagnosis of exclusion.
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